Can-Fite BioPharma CANF
NYSE CANF
$2.19 -0.03 (-1.34%)
As of: Sep 10, 2026 · 9:36 AM EDT

Can-Fite BioPharma (CANF) Total Debt (2014)

Can-Fite BioPharma (CANF) posted Total Debt of $21.2 million for Q4 2014.

Analysis

Can-Fite BioPharma (CANF) Total Debt (2014) Analysis & Trends

Can-Fite BioPharma (CANF) has 1 years of Total Debt data on file, last reported at $21.2 million in Q4 2014.

  • For the quarter ending Q4 2014, Total Debt changed N/A year-over-year to $21.2 million; the trailing twelve-month figure through Dec 2014 stood at $21.2 million (changed N/A YoY), and the FY2014 full-year result was $21.2 million, changed N/A from the prior year.
  • Total Debt was $21.2 million for Q4 2014 at Can-Fite BioPharma.
  • In the past five years, Total Debt ranged from a high of $21.2 million in Q4 2014 to a low of $21.2 million in Q4 2014.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Johnson & Johnson 649.12 Bn 628.36 Bn 17.26 Bn 60.73 Bn
2 AbbVie 445.86 Bn 439.29 Bn 12.70 Bn 70.82 Bn
3 Merck 362.13 Bn 354.99 Bn 12.21 Bn 53.91 Bn
4 Novartis Ag 268.88 Bn 261.19 Bn 11.24 Bn 9.59 Bn
5 Pfizer 156.96 Bn 145.26 Bn 10.94 Bn 63.19 Bn
6 Sanofi 52.26 Bn 44.88 Bn 10.79 Bn 25.19 Bn
7 Revolution Medicines 42.98 Bn 42.98 Bn - -
8 Incyte 25.13 Bn 20.59 Bn 1.57 Bn 38.81 Mn
9 United Therapeutics 21.56 Bn 18.90 Bn 683.80 Mn -
10 Can-Fite BioPharma 1.80 Mn -1.19 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2014 21.17 Mn